Improving PSMA-RPT Treatment for Advanced Prostate Cancer
Official title: Multidimensional analyses to improve PSMA-RPT efficacy in mCRPC
Funded at University of California Los Angeles · NIH-11122259 · Data updated 2026-11-12
This project aims to find better ways to make a special radiation treatment called PSMA-RPT work more effectively for patients with advanced prostate cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | July 12, 2023 |
| Project end | March 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $584,235 |
| NIH project number | 5R01CA279094-03 |
| Project ID | NIH-11122259 on NIH RePORTER |
Who could benefit from this research
✓Could help
This research is relevant for patients diagnosed with metastatic castration-resistant prostate cancer who are currently receiving or may receive PSMA-RPT.
✕Less likely to help
Patients without metastatic castration-resistant prostate cancer would not directly benefit from this specific research.
What this research studies
We know that a special radiation treatment called PSMA-RPT helps patients with advanced prostate cancer, but it doesn't always work perfectly, and cancer can return. This project is looking closely at the cancer's genes, molecules, and immune system to understand why some treatments work better than others. We are studying how the treatment affects cancer cells and the body's immune response, especially focusing on certain pathways like TP53 and cGAS/STING. Our goal is to discover new ways to make PSMA-RPT more powerful and lasting for patients.
Why it matters
Potential benefit: If successful, this work could lead to new strategies to significantly improve the effectiveness and long-term success of PSMA-RPT for patients with metastatic castration-resistant prostate cancer.
How similar studies have gone: While PSMA-RPT has shown some success in patients, this project explores novel combinations and molecular pathways to enhance its efficacy, building on existing knowledge.
Where this research is happening
-
University of California Los Angeles
Los Angeles, United States Active
Researchers
- Principal investigator: Czernin, Johannes — University of California Los Angeles
- Study coordinator: Czernin, Johannes
Related research
Other NIH-funded projects on the same topics.
-
Dual Targeting of B7-H3 in metastatic prostate cancer
A Johns Hopkins team is testing two targeted therapies against B7-H3 to help people with metastatic castration-resistant prostate cancer feel better and show tumor responses.
-
Hyperactive methylation in a hard-to-treat prostate cancer subtype
Researchers are studying a newly identified methylation-heavy group of advanced prostate cancer to understand its biology and find clues for better treatments.
-
Extending Benefit by Targeting Resistant Lesions in mCRPC
A cancer center plans to identify on-treatment resistant spots in men with metastatic castration-resistant prostate cancer and then use targeted local therapy to those spots while systemic treatment continues.
-
CXCR1/2 inhibitor plus enzalutamide for abiraterone-resistant metastatic prostate cancer
A phase 2 study tests whether adding SX-682 to enzalutamide helps men with advanced prostate cancer that no longer responds to abiraterone.
-
Multidimensional approach to boost PSMA-RPT success in advanced prostate cancer
A cancer research grant aims to better understand why PSMA-targeted radiopharmaceutical therapy works sometimes but not always for advanced prostate cancer, with the goal of making treatments more effective for patients who need them.
-
Targeted radiation approach for prostate cancer without continuous castration
A study testing a targeted radiation plan for men with metastatic castration-resistant prostate cancer to improve outcomes and quality of life by avoiding continuous castration for those receiving PSMA-directed therapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.